At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 58 enrolled
Drug / intervention
Placebo +1 moredrug
Likely dose
Curcumin 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users: a Randomized Clinical Trial of Curcumin
In Brief
A Phase 4 clinical trial evaluating Placebo and Curcumin for Bleeding and 2 related conditions. Completed, enrolled 58 participants across 1 site.
Detailed Summary
The investigators plan to study the effects of curcumin, the active ingredient in the spice turmeric, on the irregular bleeding experienced by women who use the contraceptive implant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBleeding, Implants, Breakthrough Bleeding
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
First PostedDec 2019
Enrollment StartApr 2020
Primary CompletionNov 2022
Study CompletionAug 2023
TodayJul 2026
First PostedDec 20, 2019
Enrollment StartApr 15, 2020
Primary CompletionNov 5, 2022
Study CompletionAug 1, 2023
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 6.5 years ago
Interventions
Placebodrug
Placebo (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding
Curcumindrug
Curcumin 600 mg (oral) once daily for 30 days. Treatment to be started after 3 consecutive days of bleeding